Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
Delibasi
Tuncay
T
Altundag
Kadri
K
Kanlioglu
Yesim
Y
D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D001859:Bone Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology; D004164:Diphosphonates / Q000009:adverse effects* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007568:Jaw / Q000378:metabolism; D007571:Jaw Diseases / Q000139:chemically induced* / Q000150:complications / Q000378:metabolism; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D010010:Osteoclasts / Q000378:metabolism; D010020:Osteonecrosis / Q000139:chemically induced* / Q000150:complications / Q000378:metabolism
D050071:Bone Density Conservation Agents; D004164:Diphosphonates